Until now, effective treatment for hormone-resistant prostate cancer has been limited to docetaxel, but in the past five years, five new drugs with different mechanisms of action have been shown to extend overall survival in phase III clinical trials, as summarized by Dr. Sridhar from Canada, including the androgen synthesis inhibitor abiraterone acetate The median survival for prostate cancer after metastasis is only 2-3 years, but despite this, the current treatment of hormone-resistant prostate cancer has been successful. The current findings in the field of hormone-resistant prostate cancer treatment are encouraging, and it is crucial to understand the mechanisms by which tumors become resistant to new drugs and to investigate new treatment strategies that may eventually lead to the application of drugs in the early stages of the disease in order to achieve a cure. It is important to recognize that these drugs are not yet the ultimate cure for the disease and that much work remains to be done in this area.